Remyelination varies between and within lesions in multiple sclerosis following bexarotene

Autor: J. William L. Brown, Ferran Prados, Daniel R. Altmann, Baris Kanber, Jonathan Stutters, Nick G. Cunniffe, Joanne L. Jones, Zoya G. Georgieva, Edward J. Needham, Cyrus Daruwalla, Claudia Gandini Wheeler‐Kingshott, Peter Connick, Siddharthan Chandran, Robin Franklin, David MacManus, Rebecca Samson, Alasdair Coles, Declan Chard

Publikováno v: Annals of Clinical and Translational Neurology, Vol 9, Iss 10, Pp 1626-1642 (2022)

Abstract Objective In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, or even reverse, disability. We recently trialled bexa

Externí odkaz: https://doaj.org/article/1826f850492946098c69aca992564af5

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

Autor: Benedict D. Michael, Cordelia Dunai, Edward J. Needham, Kukatharmini Tharmaratnam, Robyn Williams, Yun Huang, Sarah A. Boardman, Jordan Clark, Parul Sharma, Krishanthi Subramaniam, Greta K. Wood, Ceryce Collie, Richard Digby, Alexander Ren, Emma Norton, Maya Leibowitz, Soraya Ebrahimi, Andrew Fower, Hannah Fox, Esteban Tato, Mark Ellul, Geraint Sunderland, Marie Held, Claire Hetherington, Franklyn Nkongho, Alish Palmos, Alexander Grundmann, James P. Stewart, Michael Griffiths, Tom Solomon, Gerome Breen, Alasdair Coles, Jonathan Cavanagh, Sarosh R. Irani, Angela Vincent, Leonie Taams, David K. Menon

We measured brain injury markers, inflammatory mediators, and autoantibodies in 203 participants with COVID-19; 111 provided acute sera (1-11 days post admission) and 56 with COVID-19-associated neurological diagnoses provided subacute/convalescent s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04dbc748be4dd18b2efc2d30639e3d84
https://doi.org/10.1101/2023.04.03.23287902

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

Autor: Charles ffrench-Constant, David G. MacManus, Jonathan Stutters, Owen R Pearson, DT Chard, Baris Kanber, Edward Needham, Zoya Georgieva, Joanne L. Jones, David Rog, Alasdair Coles, Rebecca S. Samson, Claudia A. M. Wheeler-Kingshott, J William L Brown, Ferran Prados, Peter Connick, Andrew W. Michell, Siddharthan Chandran, James Overell, Daniel R. Altmann, Paul D Flynn, Robin J.M. Franklin, Nick G Cunniffe, Carla Moran

Publikováno v: Brown, J W L, Cunniffe, N G, Prados, F, Kanber, B, Jones, J L, Needham, E, Georgieva, Z, Rog, D, Pearson, O R, Overell, J, Macmanus, D, Samson, R S, Stutters, J, Ffrench-constant, C, Gandini Wheeler-kingshott, C A M, Moran, C, Flynn, P D, Michell, A W, Franklin, R J M, Chandran, S, Altmann, D R, Chard, D T, Connick, P & Coles, A J 2021, ' Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study ', The Lancet Neurology, vol. 20, no. 9, pp. 709-720 . https://doi.org/10.1016/S1474-4422(21)00179-4

Summary Background Progressive disability in multiple sclerosis occurs because CNS axons degenerate as a late consequence of demyelination. In animals, retinoic acid receptor RXR-gamma agonists promote remyelination. We aimed to assess the safety and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d23ac9c1ac3d67ed9a8f869f9bb4d7
https://doi.org/10.1016/s1474-4422(21)00179-4

Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis.

Autor: Jessica L Davies, Sara Thompson, Harpreet Kaur-Sandhu, Stephen Sawcer, Alasdair Coles, Maria Ban, Joanne Jones

Publikováno v: PLoS ONE, Vol 11, Iss 7, p e0158327 (2016)

Multiple sclerosis is an autoimmune disease of the central nervous system. Genome wide association studies have identified over 100 common variants associated with multiple sclerosis, the majority of which implicate immunologically relevant genes, pa

Externí odkaz: https://doaj.org/article/ba17d79309fa4e63ab24edbe054cc384

GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop

Autor: Brian K. Fiske, Simon R.W. Stott, Mart Saarma, Camille Carroll, David Eidelberg, Roger A. Barker, Richard K. Wyse, Patrik Brundin, Amber D. Van Laar, Jamie L. Eberling, David T Dexter, Henri J. Huttunen, Merja H. Voutilainen, Adrian P. Kells, Jeffrey H. Kordower, Eros Bresolin, Alasdair Coles, Leah Mursaleen, Don M. Gash, Karl Kieburtz, Alan L Whone, Howard J. Federoff, A. Jon Stoessl, Sigrid Booms, Lyndsey Isaacs, Massimo S. Fiandaca, Anthony E. Lang, Codrin Lungu, Krystof S. Bankiewicz, Helen Matthews, Anders Björklund

Publikováno v: Journal of Parkinson's disease, vol 10, iss 3
Barker, R A, Bjorklund, A, Gash, D M, Whone, A, Van Laar, A, Kordower, J H, Bankiewicz, K, Kieburtz, K, Saarma, M, Booms, S, Huttunen, H J, Kells, A, Fiandaca, M S, Stoessl, A J, Eidelberg, D, Federoff, H, Voutilainen, M, Dexter, D T, Eberling, J, Brundin, P, Isaacs, L, Mursaleen, L, Bresolin, E, Carroll, C, Coles, A, Fiske, B, Matthews, H, Lungu, C, Wyse, R K, Stott, S & Lang, A E 2020, ' GDNF and Parkinson's Disease : Where Next? A Summary from a Recent Workshop ', Journal of Parkinson's Disease, vol. 10, no. 3, pp. 875-891 . https://doi.org/10.3233/JPD-202004
Journal of Parkinson's Disease

The concept of repairing the brain with growth factors has been pursued for many years in a variety of neurodegenerative diseases including primarily Parkinson's disease (PD) using glial cell line-derived neurotrophic factor (GDNF). This neurotrophic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a88877f6c9a7279991a0d0736af61ec6
https://doi.org/10.3233/jpd-202004